Number sleven, Interesting info which opens up many questions: Is there a path forward for AMRN to benefit from this Mochida version? Given that it increases the blood absorption levels of EPA and is a one-a-day product. Could it be manufactured at a reduced cost than Vascepa for the same level of EPA in blood plasma? Having a one-a-day product should increase compliance. Is this something that could get FDA approval for CVD? Where does AMRN have exclusive rights to sell this? The US? Europe? China? Obviously, we do not know. Would be nice someday to find out if this Mochida version is something that could provide significant benefit to AMRN (or an acquirer) someday.
News 
Market Data 
Discover 
AI
